Literature DB >> 8363366

Penicillin-binding proteins of Rhodococcus equi: potential role in resistance to imipenem.

P Nordmann1, M H Nicolas, L Gutmann.   

Abstract

Rhodococcus equi is a gram-positive coccobacillus which, like other members of the order Actinomycetales, is increasingly reported as an opportunistic pathogen in patients with AIDS. The use of combinations of antibiotics that include imipenem (IMP) has been suggested for the treatment of patients infected with R. equi. An antagonism between IMP, meropenem, cefoxitin, ceftriaxone, moxalactam, and oxacillin and other beta-lactams, such as penicillin, amoxicillin, cephalothin, and ticarcillin, was detected in vitro both on Mueller-Hinton agar and in broth for all 10 IMP-susceptible R. equi strains examined. To study the mechanism of the antagonism between beta-lactams, a mutant with decreased susceptibility to IMP (isolate IpR) was selected in vitro from a susceptible clinical isolate of R. equi (isolate IpS). IpR exhibited decreased susceptibility to IMP, meropenem, cefoxitin, ceftriaxone, moxalactam, and oxacillin but not to penicillin, amoxicillin, cephalothin, or ticarcillin. No beta-lactamase was found in IpS, IpS cultured with antagonistic beta-lactams, or IpR strains. Labeling of penicillin-binding proteins (PBPs) revealed four PBPs with molecular masses of ca. 59, 56, 43, and 26 kDa in IpS. In IpR, PBP 3 disappeared and was replaced by PBP 3a of 40 kDa. The 50% saturation of PBP 3 and PBP 3a by the carbapenems correlated with the MICs of these antibiotics, respectively, for IpS and IpR strains. However, PBP 3a was not detected in IpS when IpS was cultured in the presence of beta-lactams, with which antagonism was observed. The present work describes the PBPs of R. equi and reports that IMP resistance in R. equi is related to an altered PBP pattern.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363366      PMCID: PMC187983          DOI: 10.1128/AAC.37.7.1406

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Imipenem/vancomycin for Rhodococcus equi pulmonary infection in HIV-positive patient.

Authors:  R M Rouquet; D Clave; P Massip; N Moatti; P Leophonte
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

2.  Imipenem/teicoplanin for Rhodococcus equi pulmonary infection in AIDS patients.

Authors:  P Chavanet; B Bonnotte; D Caillot; H Portier
Journal:  Lancet       Date:  1991-03-30       Impact factor: 79.321

3.  Corynebacterium equi: in vitro susceptibility to twenty-six antimicrobial agents.

Authors:  J B Woolcock; M D Mutimer
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

Review 4.  Rhodococcus equi infection in patients with and without human immunodeficiency virus infection.

Authors:  R L Harvey; J C Sunstrum
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

Review 5.  Rhodococcus equi infection in the patient with AIDS: literature review and report of an unusual case.

Authors:  W Emmons; B Reichwein; D L Winslow
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

6.  In-vitro antimicrobial susceptibility of Rhodococcus equi.

Authors:  P Nordmann; E Ronco
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

7.  Properties of the penicillin-binding proteins of Escherichia coli K12,.

Authors:  B G Spratt
Journal:  Eur J Biochem       Date:  1977-01

8.  Altered penicillin-binding components in penicillin-resistant mutants of Bacillus subtilis.

Authors:  C E Buchanan; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1976-06       Impact factor: 11.205

9.  Corynebacterium equi: a review of 12 cases of human infection.

Authors:  L L Van Etta; G A Filice; R M Ferguson; D N Gerding
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

10.  Lung abscess due to Corynebacterium equi. Report of the first case in a patient with acquired immune deficiency syndrome.

Authors:  J H Samies; B N Hathaway; R M Echols; J M Veazey; V A Pilon
Journal:  Am J Med       Date:  1986-04       Impact factor: 4.965

View more
  4 in total

Review 1.  Carbapenems: past, present, and future.

Authors:  Krisztina M Papp-Wallace; Andrea Endimiani; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

2.  Correlation between antibiotic resistance, phage-like particle presence, and virulence in Rhodococcus equi human isolates.

Authors:  P Nordmann; M Keller; F Espinasse; E Ronco
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

Review 3.  Rhodococcus equi and Arcanobacterium haemolyticum: two "coryneform" bacteria increasingly recognized as agents of human infection.

Authors:  R Linder
Journal:  Emerg Infect Dis       Date:  1997 Apr-Jun       Impact factor: 6.883

4.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.